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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to acetic 
acid and maintenance of normal blood pressure (ID 1447) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to acetic acid and maintenance of normal blood pressure. The scientific substantiation is 
based on the information provided by the Member States in the consolidated list of Article 13 health 
claims and references that EFSA has received from Member States or directly from stakeholders. 
The food that is the subject of the health claim is apple vinegar drink. From the references provided 
for the scientific substantiation of the claim, the Panel assumes that the food constituent which is 
responsible for the claimed effect is acetic acid. The Panel considers that acetic acid is sufficiently 
characterised. 
The claimed effect is “helps maintain vascular health”. The target population is assumed to be the 
general population. In the context of the clarifications provided by Member States, the Panel assumes 
that the claimed effect refers to the maintenance of normal blood pressure. The Panel considers that 
maintenance of normal blood pressure is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that although one animal study showed an 
effect of acetic acid administration on systolic blood pressure, results from two human intervention 
studies are conflicting, and that a sustained effect of orally administered acetic acid on blood pressure 
is unlikely because of its rapid absorption and clearance from the circulation after consumption.   
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of acetic acid and maintenance of normal blood pressure.  
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-2184, adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent (ID 1447) 
The food that is the subject of the health claim is apple vinegar drink.  
From the references provided for the scientific substantiation of the claim, the Panel assumes that the 
food constituent which is responsible for the claimed effect is acetic acid. Acetic acid is an organic 
acid produced by bacterial fermentation in the manufacturing of vinegar. Acetic acid can be measured 
in foods and drinks by established methods.  
The Panel considers that the food constituent, acetic acid, which is the subject of the health claim, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health (ID 1447) 
The claimed effect is “helps maintain vascular health”. The Panel assumes that the target population 
is the general population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to the maintenance of normal blood pressure. 
Blood pressure is the pressure (force per unit area) exerted by circulating blood on the walls of blood 
vessels. Elevated blood pressure, by convention above 140 mmHg (systolic) and/or 90 mmHg 
(diastolic), may compromise the normal arterial and cardiac function. 
The Panel considers that maintenance of normal blood pressure is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect (ID 1447) 
The references provided for the scientific substantiation of the claim included two links to web pages 
in Japanese, one article in Japanese reporting on a human intervention study on the effects of a drink 
containing vinegar on blood pressure, which could not be retrieved and for which no translation into 
an EU language was provided, and narrative reviews which were either not related to the claimed 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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effect or did not contain any original data which could be used for the scientific substantiation of the 
claim. The Panel considers that no conclusions can be drawn from these references for the scientific 
substantiation of the claim.  
One article in Japanese with a full-text English translation was provided which reported on a human 
intervention study on the effects of apple and rice vinegar drinks on blood pressure (Kajimoto et al., 
2003). A total of 104 adult subjects with high normal blood pressure or grade I hypertension (systolic 
blood pressure (SBP) between 130 and 159 mmHg, diastolic blood pressure (DBP) between 85 and 
99 mmHg) were recruited. Need of emergency antihypertensive therapy, cerebrovascular disorders, 
history of cardiac failure, atrial fibrillation or serious arrhythmia, severe liver or kidney dysfunction, 
and uncontrolled diabetes were among the exclusion criteria. Medication use among participants, 
including the use of antihypertensive medications, was not reported. Six subjects were excluded from 
data analysis because of severe renal dysfunction (one), out of range blood pressure (one) and 
inability to start the trial due to personal reasons (four). After a two-week run-in period, subjects were 
randomised to consume 100 mL of a drink containing 15 g of apple vinegar (n=33, 17 female) or rice 
vinegar (n=34, 17 female) with acetic acid (750 mg) at a concentration of 5 % (w/v), or 100 mL of a 
placebo drink containing 1 g of lactic acid (n=31, 16 female) for 10 weeks, followed by a four-week 
observation period with no drinks. The test and placebo drinks were otherwise comparable regarding 
their macronutrient composition and their content of potassium, sodium, calcium and vitamin C, and 
subjects were not able to distinguish them on the basis of their organoleptic properties. Office blood 
pressure was measured after an overnight fast using a standard protocol. Data were analysed for the 
whole study population, and separately for subjects with high normal blood pressure and grade I 
hypertension. The Panel notes that it is not stated in the publication whether sub-group comparisons 
were pre-planned, and considers that no conclusions can be drawn from these analyses for the 
scientific substantiation of the claim. SBP significantly decreased in the apple and rice vinegar groups 
compared to placebo at weeks 2 (-6.6 mmHg and -7.6 mmHg vs. +1.0 mmHg, respectively, p<0.05), 6 
(-12.8 mmHg and -11.6 mmHg vs. -3 mmHg, respectively, p<0.01), 8 (-11.2 mmHg and -12.9 mmHg 
vs. -2.2 mmHg, respectively, p<0.01) and 10 of the study (-12.0 mmHg and -9.6 mmHg vs. 
-2.3 mmHg, p<0.01 and p<0.05, respectively), whereas no significant differences were observed 
between groups at week 4 of the study. No interaction between test drinks and intake duration on 
blood pressure values was observed. Follow-up values were not significantly different from baseline 
in any of the groups. No significant differences between the apple and the rice vinegar groups were 
observed at any time point. No significant differences in DBP, heart rate, body weight or body 
composition were observed between the three groups throughout the study.  
Another human intervention study retrieved by the Panel reported on the effects on blood pressure of 
apple vinegar drinks containing different amounts of acetic acid (Kondo et al., 2009). After a 
three-week run-in period, a total of 155 adult overweight subjects (out of 175 recruited), who were not 
using medications, were randomised to consume 500 mL of a placebo drink containing 1,250 mg 
lactate (n=50, 18 female), or 500 mL of a drink containing 15 mL (n=54, 20 female) or 30 mL (n=51, 
20 female) of apple vinegar daily for 10 weeks, followed by a four-week observation period with no 
test or placebo drinks. The acetic acid content of the drinks was 0, 750 and 1,500 mg, respectively. 
The test and placebo drinks were otherwise comparable regarding their macronutrient composition 
and their content of potassium, sodium, calcium and vitamin C, and subjects were not able to 
distinguish them on the basis of their organoleptic properties. Office blood pressure was measured 
after an overnight fast using a standard protocol. Compared to placebo SBP significantly decreased in 
the apple vinegar group containing 1,500 mg acetic acid at week 12 only (-4.5 mmHg vs. +0.1 mmHg, 
p<0.01). No other significant differences on blood pressure were observed between the three groups 
for the entire duration of the study. The Panel notes that differences in body weight changes during 
the study between the high acetic acid dose group and the placebo group (reported to be about -3 kg) 
could account for the significant differences in SBP values observed at week 12 of the study. The 
Panel also notes that the results from this study are in conflict with those obtained by Kajimoto et al. 
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(2003), who reported a significant effect (of about -10mmHg) on SBP with 750 mg/day of acetic acid, 
with effects that were already statistically significant after two weeks of consumption. 
One study on spontaneously hypertensive rats (SHR) was also provided (Kondo et al., 2001). 
Four-week old (n=18) SHR were randomised to consume standard laboratory diets with a 6.0 % 
solution (w/w) of either acetic acid (containing 46.2 g/L acetic acid), vinegar (containing 46.2 g/L 
acetic acid) or no solution (control) for eight weeks after a six-week run-in period in which only the 
standard diet was consumed. No significant differences in body weight, water consumption or food 
intake were observed between groups. SBP (p<0.05) and plasma renin activity (p<0.01) significantly 
decreased in the acetic acid and vinegar groups compared to placebo, whereas no significant 
differences were observed in angiotensin I-converting enzyme activity in various organs, or in plasma 
angiotensin II. Plasma aldosterone concentrations significantly decreased in the vinegar group 
compared to the acetic acid group and the control group (p<0.05). No significant differences between 
the acetic acid and the vinegar groups were observed during the study with respect to SBP values. It 
was hypothesised that acetic acid could exert the claimed effect by reducing renin secretion, and by 
inducing a subsequent decrease in angiotensin II. The Panel notes that this study does not provide 
clear evidence on a mechanism by which acetic acid could exert the claimed effect.  
A recently published randomised, cross-over, human intervention study retrieved by the Panel 
(Sugiyama et al., 2010), addressed the bioavailability of acetate from two vinegar supplements (as 
capsules or drinks) compared to water as reference in 30 healthy Japanese subjects. The vinegar drink 
(100 mL containing 750 mg acetic acid) and water control were consumed after an overnight fast. 
Serum acetate concentrations increased immediately after intake of the vinegar drink, peaked at 
15 min and returned to baseline at 90 min. No significant changes in serum acetate concentrations 
were observed after the water control. The Panel notes that acetic acid in the vinegar drink at the dose 
used in the human intervention study by Kajimoto et al. (2003) was rapidly absorbed and cleared from 
the circulation after consumption, and thus the Panel considers that an effect of orally administered 
acetic acid on blood pressure lasting 12 hours or more (e.g. after an overnight fast) is unlikely.  
In weighing the evidence, the Panel took into account that although one animal study showed an 
effect of acetic acid administration on systolic blood pressure, results from two human intervention 
studies are conflicting, and that a sustained effect of orally administered acetic acid on blood pressure 
is unlikely because of the rapid absorption and clearance from the circulation after consumption.   
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of acetic acid and maintenance of normal blood pressure.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, acetic acid, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect is “helps maintain vascular health”. The target population is assumed to be 
the general population. In the context of the clarifications provided by Member States, it is 
assumed that the claimed effect refers to the maintenance of normal blood pressure. 
Maintenance of normal blood pressure is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of acetic 
acid and maintenance of normal blood pressure.  
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DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-2184). 
The scientific substantiation is based on the information provided by the Member States in the 
consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
REFERENCES 
Kajimoto O, Ohshima Y, Tayama K, Hirata H, Nishimura A and Tsukamoto Y, 2003. Hypotensive 
effects of drinks containing vinegar on high normal blood pressure and mild hypertensive subjects. 
Kenko Eiyo Shokuhin Kenkyu (Journal of Nutritional Food), 6, 51-68. 
Kondo S, Tayama K, Tsukamoto Y, Ikeda K and Yamori Y, 2001. Antihypertensive effects of acetic 
acid and vinegar on spontaneously hypertensive rats. Bioscience, Biotechnology, and 
Biochemistry, 65, 2690-2694. 
Kondo T, Kishi M, Fushimi T, Ugajin S and Kaga T, 2009. Vinegar intake reduces body weight, body 
fat mass, and serum triglyceride levels in obese Japanese subjects. Bioscience, Biotechnology, and 
Biochemistry, 73, 1837-1843. 
Sugiyama S, Fushimi T, Kishi M, Irie S, Tsuji S, Hosokawa N and Kaga T, 2010. Bioavailability of 
acetate from two vinegar supplements: capsule and drink. Journal of Nutritional Science and 
Vitaminology, 56, 266-269. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to acetic acid, including conditions of use from similar 
claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
1447 Apple vinegar drink. Helps maintain vascular 
health. 
Clarification provided 
Apple vinegar helps to 
maintain a healthy blood 
pressure. 
Apple vinegar drink helps to 
maintain vascular health. 
Conditions of use 
- The product should contain 15ml Apple vinegar with acidity of 5%w/v per serving. It is not 
advisable to take this product on an empty stomach, as irritation might be felt. 
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GLOSSARY AND ABBREVIATIONS 
DBP  Diastolic blood pressure   
SBP  Systolic blood pressure  
SHR  Spontaneously hypertensive rats 
